Abstract
Today, endometrial hyperplasia (EH) is among the most relevant gynecological entities. Arterial hypertension, diabetes mellitus and obesity, the combination of which is referred to as metabolic syndrome, are the key risk factors of EH. The incidence of EH and endometrial cancer grows proportionally based on the rapid increase in the prevalence of this set of symptoms among patients in the 21st century. Currently, there is a clear histological gradation of EH into atypical form and EH without atypia, which represents a key factor of the clinical management strategy (conser-vative or surgical) determination. However, high EH relapse rate after conservative treatment is the most important challenge of EH. In this re-gard, it is necessary to consider modern options for prevention of recurrent EH without atypia in patients of different ages.
Key words: endometrial hyperplasia, levonorgestrel, gestagens, prevention of recurrent endometrial hyperplasia, combined oral contraceptives, gestodene.
Key words: endometrial hyperplasia, levonorgestrel, gestagens, prevention of recurrent endometrial hyperplasia, combined oral contraceptives, gestodene.
For citation:Orazov M.R., Radzinskii V.E., Khamoshina M.B., Dolgov E.D., Mullina I.A., Artemenko Yu.S. Recurrent endometrial hyperplasia without atypia: how to escape the vicious circle? Clinical review for general practice. 2023; 4 (9): 21–30 (In Russ.). DOI: 10.47407/kr2023.4.9.00324
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
